Drug Profile
BI 54903
Alternative Names: BI54903Latest Information Update: 10 Oct 2014
Price :
$50
*
At a glance
- Originator Boehringer Ingelheim
- Class Antiasthmatics
- Mechanism of Action Immunosuppressants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Asthma
Most Recent Events
- 10 Oct 2014 No development reported - Phase-I for Asthma (In volunteers) in Germany (Inhalation)
- 10 Oct 2014 No development reported - Phase-II for Asthma in USA (Inhalation)
- 16 Nov 2011 Boehringer Ingelheim terminates three phase II trial in Asthma in USA (NCT01397162, NCT01397201, NCT01396278)